

Press Releases

Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

Feb 4, 2020

Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Feb 3, 2020

Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial

Dec 19, 2019

Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event

Dec 4, 2019

Citius Pharmaceuticals Issues Corporate Update

Nov 8, 2019

Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference

Oct 24, 2019

Citius Pharmaceuticals to Present at the MicroCap Rodeo

Oct 15, 2019

Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial

Oct 7, 2019

Citius Provides Update on Activities From IDWeek 2019

Oct 3, 2019

Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market

Sep 27, 2019